Merz Aesthetics, a division of Merz North America (US affiliate of the global Merz Pharma Group) announced today that Ultherapy® has been named “Best Nonsurgical Skin Tightener” in the 2016 Beauty Choice Awards. This is the 3rd consecutive year Ultherapy® has been recognized by NewBeauty readers and editors in their Beauty Choice Awards. Ultherapy® is the first and only treatment FDA-cleared to non-invasively lift the eyebrow, neck, and chin, and to improve lines and wrinkles on the décolletage.

“Our continued recognition by New Beauty magazine, one of the top authorities in aesthetics, is a testament to the results physicians and patients see with Ultherapy,” said Patrick Urban, Vice President and Head of the Merz Aesthetics Device Division. “Ultherapy continues to be the top choice for physicians looking for a non-invasive solution to lifting and tightening the skin of the eyebrow, neck, and under the chin, and improve fine lines and wrinkles on the décolletage area.”

The winners of NewBeauty’s annual Beauty Choice Awards are selected by readers, editors, and beauty professionals, who cast their votes throughout the year. A complete list of Beauty Choice Award winners is included in the Winter/Spring 2016 issue of NewBeauty, currently available on newsstands and online.

“In my practice, I continue to utilize Ultherapy as my go-to treatment option for patients looking for lifting and tightening around the brow, neck, and especially, under the chin. I also love Ultherapy for the fine lines and wrinkles on the décolletage. Ultherapy is an effective treatment that provides visible and predictable results; and most importantly, patients are satisfied with the changes they see with the treatment,” stated Dr. Doris Day, Board Certified Dermatologist and founder of Day Dermatology and Associates.

For full Ultherapy® product and safety information, visit:

About Merz Aesthetics

Merz Aesthetics is a division of Merz North America, a specialty healthcare company that develops and commercializes treatment solutions in aesthetics, dermatology and neurosciences in the U.S. and Canada. As part of the Merz Pharma Group of companies, our ambition is to become the most admired, trusted and innovative aesthetics and neurotoxin company. By developing products that improve patients’ health and help them to live better, feel better and look better, Merz will continue to make significant contributions to the well-being of individuals around the world. Merz Aesthetics provides a range of treatment options, including devices, injectables and skincare, that enable physicians to use Merz technologies to treat a variety of patients and concerns. For more information about Merz Aesthetics and their U.S. product portfolio, please visit

Merz Pharma Group
With approximately 3,000 employees and 34 subsidiaries worldwide, Merz is a global leader in Aesthetics and Neurotoxins. Privately held for more than 100 years, the company is distinguished by its in-house research and development, solid financial strength and continuous growth. Complementing its unique portfolio of products for minimally invasive and non-invasive skin rejuvenation and tightening, Merz also develops neurotoxin therapy for the treatment of movement disorders. Skincare products and a range of OTC medicines are also included in offerings from the company, which is headquartered in Frankfurt, Germany. In fiscal year 2016/17, the Merz Pharma Group generated revenue of EUR 1,023.2 million. More information is available at

Download File:
03.29.2016 [ 0 KB ]

Press Contact

Merz North America

Emily Browder
Corporate Communications


Phone: +1 919.582.8114